Anixa Biosciences and Curia will Develop Final Formulation for Breast Cancer Vaccine in Preparation for Phase 2 Clinical Trial

On November 18, 2026 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported that it will work with Curia, a leading global contract development and manufacturing organization (CDMO), to provide formulation development services for Anixa’s investigational breast cancer vaccine in preparation for its upcoming Phase 2 clinical trial. The vaccine is being developed in collaboration with Cleveland Clinic.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the collaboration, Curia will support the development of a formulation designed to optimize the vaccine’s stability, consistency, and suitability for clinical manufacturing. This work represents an important step in Anixa’s preparations for Phase 2 and is intended to establish a formulation and development process capable of supporting future clinical studies and potential commercial production.

"Selection of Curia is another important milestone as we prepare to advance our breast cancer vaccine into Phase 2 clinical development," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "Our Phase 1 trial demonstrated encouraging safety and immune-response results, and we are now focused on the activities necessary to support the next stage of clinical testing. Curia brings extensive expertise in pharmaceutical formulation and manufacturing processes, and we believe their capabilities will be valuable as we work toward developing a vaccine that could ultimately help prevent breast cancer."

"Curia looks forward to providing formulation development support for Anixa’s peptide cancer vaccine," said Ranald Baillie, VP, Drug Product Development and General Manager at Curia Glasgow. "Successful formulation and product development requires looking beyond the formulation itself to understand stability, analytical performance, scalability and the requirements of aseptic manufacturing. Curia’s integrated expertise allows us to address those considerations early and develop robust processes designed to support Anixa as it advances this vaccine towards commercialization."

Anixa’s investigational breast cancer vaccine is designed to stimulate the immune system to recognize alpha-lactalbumin, a protein expressed in many breast cancers. The vaccine recently completed a Phase 1 clinical trial involving 35 women, meeting its primary endpoints and demonstrating a favorable safety and tolerability profile, with 74% of participants exhibiting protocol-defined immune responses. Anixa is preparing to advance the vaccine into Phase 2 clinical development to further evaluate its potential clinical benefits.

(Press release, Anixa Biosciences, NOV 18, 2026, View Source [SID1234674929])